Biocon Biologics signed a settlement and licence agreement with Regeneron and Bayer to commercialise biosimilar Aflibercept worldwide. The agreement follows an earlier settlement for the United States and Canada and enables global commercialisation of Yesafili®.
Source: Biocon Limited Press Release (BSE Exchange Filings) | Published on Dec 13, 2025
Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.
As quoted in the press release from Biocon Limited and its news (NSE Exchange Filings), Biocon Biologics Ltd shared details of a new settlement and licence agreement with stock exchanges. The disclosure was filed with BSE and NSE on December 13, 2025.
Biocon Biologics is a subsidiary of Biocon Limited. The agreement was signed with Regeneron and Bayer. It covers Europe and other global regions. This settlement follows an earlier agreement that covered the United States and Canada.
The company stated that all pending legal cases linked to biosimilar Aflibercept were dismissed after the agreement. The filing also states that other terms of the settlement are confidential.
Biocon Biologics signed a settlement and licence agreement for biosimilar Aflibercept.
The agreement covers Europe and other global markets.
A previous settlement already covered the United States and Canada.
The agreement was signed with Regeneron and Bayer.
Regulatory approvals for the product were already received.
The settlement allows Biocon Biologics to commercialise Yesafili®. Yesafili is a biosimilar Aflibercept with a strength of 40 mg/ml. The agreement applies to countries worldwide.
Yesafili is a vascular endothelial growth factor inhibitor. It is used to treat eye-related conditions. These conditions affect vision.
The listed uses include wet age-related macular degeneration. They also include diabetic macular oedema. Other uses relate to retinal vein occlusion and myopic choroidal neovascularisation.
The company also confirmed that Yesafili received approvals from the European Commission. Approval was also granted by the Medicines & Healthcare products Regulatory Agency in the UK.
The exchange filing states that the agreement allows the launch of Yesafili in the United Kingdom in January 2026. Launch in other settled countries is scheduled for March 2026. In some cases, the launch may take place earlier.
The filing also repeats earlier disclosures for North America. Market entry for the United States was secured in April 2025. The disclosed entry period is the second half of calendar year 2026.
Yesafili was launched in Canada earlier in 2025. Market entry for Canada was secured in March 2024.
Also read: BEL Wins Orders Worth ₹776 Crore for Defence and Strategic Electronics Systems in India
Particulars | Details |
Product | Yesafili® (Biosimilar Aflibercept 40 mg/ml) |
Agreement Type | Settlement And Licence |
Partners | Regeneron And Bayer |
Geographic Coverage | Worldwide |
Regulatory Authorities | EC And MHRA |
Disclosure Source | BSE And NSE Filings |
As per exchange data on 12 December 2025 at 15:30 PM IST, Biocon Limited's share price was ₹385.35. The stock closed higher by ₹3.60. This reflects a gain of 0.94%. The previous closing price was ₹381.75. During the session, the stock opened at ₹382.70. It reached a high of ₹388.75. It touched a low of ₹382.50. The volume-weighted average price was ₹386.46.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading